Your browser doesn't support javascript.
loading
Immunosuppression in Patients With Primary Immunodeficiency-Walking the Line.
Mustafa, S Shahzad; Rider, Nicholas L; Jolles, Stephen.
Affiliation
  • Mustafa SS; Rochester Regional Health, Division of Allergy, Immunology, and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, NY; Liberty University College of Osteopathic Medicine and the Liberty Mountain, Chair, Division of Clinical Informatics; Associate Professor of Pediatrics, Allergy-Immunology Medical Group, Rochester, NY. Electronic address: shahzad.mustafa@rochesterregional.org.
  • Rider NL; Liberty University College of Osteopathic Medicine and the Liberty Mountain Medical Group, Lynchburg, Va.
  • Jolles S; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.
J Allergy Clin Immunol Pract ; 10(12): 3088-3096, 2022 Dec.
Article in En | MEDLINE | ID: mdl-36049628
Individuals with primary immunodeficiency (PIDD) experience not only infectious complications but also immune dysregulation leading to autoimmunity, inflammation, and lymphoproliferative manifestations. Management of these complications often requires treatment with additional immunosuppressive medications, which pose an additional risk of infectious complications. Immunosuppression in individuals with PIDD therefore requires careful assessment and consideration of risks and benefits. Medications should be closely monitored, and strategies for risk mitigation of adverse events considered, such as exposure reduction, appropriate vaccination, use of antibiotics/antivirals, and optimization of immunoglobulin replacement therapy. In a subset of individuals who are not tolerating immune modulation or experiencing disease progression despite appropriate interventions, hematopoietic stem-cell transplantation is a management option.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunosuppression Therapy / Hematopoietic Stem Cell Transplantation Limits: Humans Language: En Journal: J Allergy Clin Immunol Pract Year: 2022 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunosuppression Therapy / Hematopoietic Stem Cell Transplantation Limits: Humans Language: En Journal: J Allergy Clin Immunol Pract Year: 2022 Document type: Article Country of publication: United States